The World First Liquid Formulation of Recombinant Botulinum Toxin Type A Has Obtained IND Approval by the FDA.

MingMed Biotechnology, a company focused on drug development, has received FDA approval for its Investigational New Drug (IND) application for YY003, the world's first liquid formulation of recombinant Botulinum Toxin Type A (BoNT/A). The liquid formulation, packaged in a pre-filled syringe, is intended for the treatment of glabellar lines. Claruvis Pharmaceutical, a subsidiary of MingMed Biotechnology, has completed Phase III clinical trials for the treatment of medium to severe glabellar lines and has achieved positive results. The company has also started a Phase II clinical trial for the treatment of adult upper arm spasm in China. This approval is seen as a significant milestone in the botulinum toxin market. [Extracted from the article]